• EDI3 Inhibition Reduces Growth in HER2-Resistant Breast Canc

  2026-05-01

  Keller et al. identify glycerophosphodiesterase EDI3 as a metabolic vulnerability in ER-HER2+ breast cancer cells resistant to HER2-targeted therapy. Targeting EDI3 impairs cell viability and tumor growth, pointing to new therapeutic opportunities in overcoming resistance.

• Cy5 Goat Anti-Mouse IgG (H+L) Antibody: Signal Amplification

  2026-05-01

  Explore the advanced mechanism and scientific rationale behind the Cy5 Goat Anti-Mouse IgG (H+L) Antibody for high-sensitivity immunoassays. This article uniquely dissects signal amplification strategies and cross-domain innovations with practical assay guidance.

• HRP Goat Anti-Rabbit IgG (H+L) Antibody: Protocol and QC Gui

  2026-04-30

  The HRP Goat Anti-Rabbit IgG (H+L) Antibody (SKU K1223) addresses the need for high-specificity detection of rabbit primary antibodies in immunoassays such as Western blot, ELISA, and IHC. Researchers should implement it strictly for research applications, as it is not intended for diagnostic or clinical use. Proper adherence to storage and workflow recommendations is critical for reproducibility and signal sensitivity.

• Palonosetron Hydrochloride in CINV: Mechanisms and Evidence

  2026-04-30

  Ruhlmann and Herrstedt's review elucidates palonosetron hydrochloride’s unique pharmacologic features and its superior efficacy in preventing chemotherapy-induced nausea and vomiting (CINV), especially in delayed phases. Their synthesis of clinical and preclinical data provides a benchmark for optimizing antiemetic regimens in oncology, with implications for future research and clinical protocols.

• Mutational Landscapes in Myeloma Cell Lines: Drivers and Res

  2026-04-29

  This study delivers the first comprehensive exome-wide analysis of human multiple myeloma cell lines, mapping mutations across key genes and pathways linked to tumor progression and drug resistance. The resulting resource enhances model selection and guides future research into targeted therapies for hematological malignancies.

• PP 2 (AG 1879): Precision Src Inhibition in Cancer and Vascu

  2026-04-29

  PP 2 (AG 1879) unlocks robust, selective Src kinase inhibition for dissecting cancer proliferation, immune signaling, and vascular mechanisms. This guide delivers optimized protocols, workflow enhancements, and troubleshooting insights to maximize reproducibility and translational impact using APExBIO’s proven reagent.

• T7 RNA Polymerase: Precision RNA Synthesis for Advanced Work

  2026-04-28

  Harnessing the high specificity of T7 RNA Polymerase, researchers can streamline in vitro transcription for RNA vaccine production, antisense RNA studies, and more. This guide delivers scenario-driven protocols, troubleshooting strategies, and actionable insights anchored in recent mRNA vaccine breakthroughs and comparative benchmarking.

• EAAT2 Regulates Macrophage Inflammatory Polarization via mTO

  2026-04-28

  This study uncovers a mechanistic link between the excitatory amino acid transporter EAAT2 and inflammatory macrophage polarization. The authors demonstrate that lysosomal EAAT2 sustains mTORC1 activation in macrophages, shaping their pro-inflammatory phenotype and offering new therapeutic angles for inflammatory and metabolic diseases.

• PP 1: Precision Src Inhibition for Translational Cancer Rese

  2026-04-27

  This thought-leadership article explores the mechanistic and translational potential of PP 1, a potent Src family tyrosine kinase inhibitor, for cancer research and immune modulation. Blending insights from the latest prostate cancer studies with strategic guidance for translational scientists, we examine how PP 1 enables deeper mechanistic dissection, biomarker discovery, and clinical innovation. The article benchmarks PP 1 against the competitive landscape, details protocol parameters, and provides a forward-looking perspective on its role in next-generation oncology workflows.

• Balsalazide Disodium Dihydrate: Mechanisms and Translational

  2026-04-27

  Explore the advanced mechanisms and translational impact of Balsalazide disodium in inflammation research. This article reveals deeper scientific insights and assay guidance distinct from existing resources.

• Scenario-Driven Solutions with AT-406 (SM-406) in Cancer Res

  2026-04-26

  This in-depth, scenario-driven article equips biomedical researchers with validated, data-backed strategies for leveraging AT-406 (SM-406) (SKU A3019) in apoptosis, viability, and cytotoxicity assays. Drawing on published performance metrics, workflow guidance, and peer-reviewed literature, we demonstrate how AT-406 ensures reliable pathway activation, reproducibility, and practical advantages for cancer research.

• CD24-Driven Ectosome Formation in B Lymphocytes: PI3K/mTORC2

  2026-04-25

  This study uncovers the molecular mechanisms by which CD24 regulates the formation of bioactive ectosomes in B lymphocytes, focusing on the PI3K/mTORC2/ROCK/actin pathway and its upstream regulation by acid sphingomyelinase (aSMase). These findings clarify the role of specific signaling axes in extracellular vesicle (EV) biogenesis, with implications for understanding B cell development and immune communication.

• IL-34-CD36 Axis Drives Immune Evasion in p53-Inactivated Tum

  2026-04-24

  This study reveals that p53 inactivation in liver cancer leads to interleukin-34 secretion by cancer stem cells, promoting immunosuppressive tumor-associated macrophage (TAM) polarization via the IL-34-CD36 axis. These findings illuminate a novel pathway for tumor immune escape and suggest potential strategies for targeting immunotherapy-resistant cancers.

• AO/PI Staining Solution: Precision in Fluorescent Cell Count

  2026-04-24

  AO/PI Staining Solution empowers researchers with high-fidelity fluorescent cell viability assays, surpassing trypan blue in both accuracy and debris exclusion. Its optimized workflow ensures robust live/dead discrimination in challenging samples, supporting breakthroughs in inflammation and apoptosis research.

• Mutational Landscape in Myeloma Cell Lines: Drivers and Drug

  2026-04-23

  This study delivers the first comprehensive exome sequencing of 30 human multiple myeloma cell lines, revealing recurrently mutated genes and pathway alterations that underpin tumor heterogeneity and resistance to therapy. The insights enable more precise model selection and inform the rational development of therapeutic strategies targeting hematological malignancies.

16007 records 1/1068 page Next 12345 下5页 Last page